Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
48 巻, 21 号
選択された号の論文の19件中1~19を表示しています
EDITORIALS
ORIGINAL ARTICLES
  • Kunihisa Miwa, Masatoshi Fujita
    2009 年 48 巻 21 号 p. 1849-1854
    発行日: 2009年
    公開日: 2009/11/02
    ジャーナル オープンアクセス
    Objective Little attention has been paid to possible cardiovascular involvement in patients with chronic fatigue syndrome (CFS), although many of their symptoms and signs suggest cardiovascular dysfunction. Possible cardiovascular symptoms and cardiac function were investigated in CFS patients.
    Methods Cardiovascular symptoms were intensively investigated and cardiac function was evaluated echocardiographically.
    Patients Fifty-three patients (23 men and 30 women, mean age: 31±7 years) with CFS under 50 years were studied.
    Results Slender build (body mass index <20 kg/m2) was common (47%). Possible cardiovascular symptoms including shortness of breath (32%), dyspnea on effort (28%), rapid heartbeat (38%), chest pain (43%), fainting (43%), orthostatic dizziness (45%) and coldness of feet (42%), were all frequent complaints. Hypotension (28%) was occasionally noted. Electrocardiograms frequently revealed right axis deviation (21%) and severe sinus arrhythmia (34%) suggesting accentuated parasympathetic nervous activity. Small heart shadow (cardiothoracic ratio ≤42%) was noted on the chest roentgenogram in 32 patients (60%). Echocardiographic examination demonstrated low cardiac indexes (<2 L/min/m2) with low stroke volume indexes (<30 mL/m2) due to a small left ventricular chamber in 19 (36%, p<0.05 vs. 8% in 36 controls). None had reduced left ventricular ejection fraction.
    Conclusion Cardiovascular symptoms are common in CFS patients. Cardiac dysfunction with low cardiac output due to small left ventricular chamber may contribute to the development of chronic fatigue as a constitutional factor in a considerable number of CFS patients.
  • Reiko Abe, Junichi Minami, Masami Ohrui, Toshihiko Ishimitsu
    2009 年 48 巻 21 号 p. 1855-1862
    発行日: 2009年
    公開日: 2009/11/02
    ジャーナル オープンアクセス
    Objective Several studies have reported a significant association of metabolic syndrome with urinary albumin excretion, high-sensitivity C-reactive protein, or chronic kidney disease; however, no study has investigated the association of metabolic syndrome with these 3 factors together in the same individual. Therefore, we conducted the present study to obtain more information on this association.
    Methods We enrolled 712 Japanese subjects without diabetes, macroalbuminuria, or medications, who entered our hospitalized health check-up program (180 women and 532 men; mean age, 53.2 years; mean body mass index, 24.1 kg/m2). Metabolic syndrome was diagnosed by 4 major definitions. Low glomerular filtration rate was defined as an estimated glomerular filtration rate of <60 mL/min/1.73 m2.
    Results Both urinary albumin excretion and high-sensitivity C-reactive protein were significantly higher in those with metabolic syndrome than without, and metabolic syndrome was an independent determinant of both. In contrast, estimated glomerular filtration rate and the prevalence of low glomerular filtration rate did not differ significantly between those with and without metabolic syndrome. Among the 5 components of metabolic syndrome and other clinical variables, systolic blood pressure was an independent determinant of urinary albumin excretion; the 5 components and low-density lipoprotein cholesterol were all independent determinants of high-sensitivity C-reactive protein; systolic blood pressure was an independent determinant of low glomerular filtration rate.
    Conclusion Metabolic syndrome is associated with vascular dysfunction and low-grade inflammation and the latter association is strong, whereas the association of metabolic syndrome with low glomerular filtration rate may be less apparent among those without diabetes, macroalbuminuria, and medications.
  • Kazuo Otake, Ryujiro Sasanabe, Rika Hasegawa, Katsuhisa Banno, Reiko H ...
    2009 年 48 巻 21 号 p. 1863-1868
    発行日: 2009年
    公開日: 2009/11/02
    ジャーナル オープンアクセス
    Objective Obstructive sleep apnea syndrome (OSAS) often accompanies obesity and diabetes mellitus. This study was performed to investigate the prevalence of glucose intolerance and to determine independent predictors for insulin resistance in patients with OSAS.
    Methods A cross-sectional study of 679 OSAS patients with an apnea-hypopnea index (AHI)≥5/h and 73 controls subjects (AHI<5/h) was done in a tertiary university-based medical center. They were assessed by nocturnal polysomnography and underwent an oral glucose tolerance test.
    Results The prevalence of diabetes mellitus in OSAS patients was higher than that of the control group (25.9% vs. 8.2%, p<0.001) and 424 patients (62.4%) received a new diagnosis of impaired glucose tolerance or diabetes mellitus. The very severe OSAS group (AHI ≥45/h) had significantly higher homeostasis model assessment of insulin resistance (HOMA-IR) and HOMA beta-cell function than the other OSAS groups (AHI<45/h) and the control group. In a logistic regression model adjusting for potential confounders: age, AHI, minimum SpO2 and body mass index (BMI), only BMI was associated with insulin resistance (HOMA-IR>3) (odds ratio: 1.272, 95% confidence interval 1.206-1.343, p<0.0001).
    Conclusion Glucose intolerance was more common in patients with OSAS. Insulin resistance was associated not with AHI but rather with BMI.
  • Ippei Kanazawa, Toru Yamaguchi, Mika Yamauchi, Toshitsugu Sugimoto
    2009 年 48 巻 21 号 p. 1869-1873
    発行日: 2009年
    公開日: 2009/11/02
    ジャーナル オープンアクセス
    Objective Accumulating evidence suggests that statins might positively affect bone metabolism. In the present study, we compared the effect of rosuvastatin with that of ezetimibe on bone turnover markers in patients with type 2 diabetes mellitus as well as hypercholesterolemia.
    Design and Methods A total of 36 Japanese patients were enrolled in this open-label study and randomized to either rosuvastatin (2.5 mg/day) or ezetimibe (10 mg/day) groups at Shimane University Hospital. Bone turnover markers, such as bone-specific alkaline phosphatase, serum osteocalcin, urinary N-terminal telopeptide of type 1 collagen, and urinary deoxypyridinoline, were collected and compared between at baseline and at 3 months of treatment in each group.
    Results Background data was not significantly different between the two groups. Total cholesterol and LDL cholesterol levels were significantly decreased at 3 months in both groups. Serum osteocalcin levels in the rosuvastatin group were significantly increased with mean changes of 0.48 (95% confidence interval; 0.05 to 0.91, p=0.03), while no other bone marker in the ezetimibe group was changed. Changes in total cholesterol or LDL cholesterol levels were not significantly correlated with the changes in bone turnover markers.
    Conclusion Rosuvastatin may have a beneficial effect on bone metabolism in patients with type 2 diabetes and hypercholesterolemia by stimulating osteoblast function and bone formation, which seems to be independent of its cholesterol-lowering effect.
  • Yuki Tsuruta, Keiko Uchida, Mitsuyo Itabashi, Wako Yumura, Kosaku Nitt ...
    2009 年 48 巻 21 号 p. 1875-1880
    発行日: 2009年
    公開日: 2009/11/02
    ジャーナル オープンアクセス
    Objective Previous studies have documented a high frequency of thrombotic events in lupus nephritis patients with antiphospholipid (aPL) antibodies in the serum, but there is little information on the impact of serum aPL antibodies on the clinical outcome of lupus nephritis. The aims of this study were to evaluate the seroprevalence of aPL antibodies in patients with lupus nephritis and assess their prognostic value in relation to long-term renal outcomes.
    Patients and Methods A retrospective analysis was undertaken in 49 patients with lupus nephritis who underwent renal biopsy. The serum aPL antibodies were monitored regularly in the patients who were followed up for a mean of 76.4±47.2 months, and possible factors associated with the long-term renal outcomes in these patients were analyzed.
    Results The overall seroprevalence of aPL antibodies was 41%. During the follow-up, 40% of aPL antibody-positive patients experienced thrombotic events. The frequency of class V lupus nephritis was lower in the aPL antibody-positive patients (6 out of the 20 aPL antibody-positive vs. 14 out of the 29 patients aPL antibody-negative patients; p=0.03). A multivariate analysis identified age (p=0.0001), eGFR at presentation (p=0.0015) and presence of hypertension (p=0.0025) as independent risk factors for the development of chronic kidney disease (CKD) with eGFR less than 60 ml/min/1.73 m2.
    Conclusion Detection of aPL antibodies in the serum of patients with lupus nephritis is useful to identify patients at risk of thrombotic events. Hypertension is associated with the probability of CKD with eGFR less than 60 ml/min/1.73 m2.
CASE REPORTS
PICTURES IN CLINICAL MEDICINES
feedback
Top